- Home
- WIA vs NBTX Comparison
WIA vs NBTX Comparison
Compare WIA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- NBTX
- Stock Information
- Founded
- WIA 2003
- NBTX 2003
- Country
- WIA United States
- NBTX France
- Employees
- WIA N/A
- NBTX N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- NBTX Health Care
- Exchange
- WIA Nasdaq
- NBTX Nasdaq
- Market Cap
- WIA 191.5M
- NBTX 201.9M
- IPO Year
- WIA N/A
- NBTX 2020
- Fundamental
- Price
- WIA $8.21
- NBTX $3.75
- Analyst Decision
- WIA
- NBTX Strong Buy
- Analyst Count
- WIA 0
- NBTX 1
- Target Price
- WIA N/A
- NBTX $12.00
- AVG Volume (30 Days)
- WIA 39.2K
- NBTX 8.9K
- Earning Date
- WIA 01-01-0001
- NBTX 09-18-2024
- Dividend Yield
- WIA 12.29%
- NBTX N/A
- EPS Growth
- WIA N/A
- NBTX N/A
- EPS
- WIA N/A
- NBTX N/A
- Revenue
- WIA N/A
- NBTX $45,220,186.00
- Revenue This Year
- WIA N/A
- NBTX N/A
- Revenue Next Year
- WIA N/A
- NBTX N/A
- P/E Ratio
- WIA N/A
- NBTX N/A
- Revenue Growth
- WIA N/A
- NBTX 526.17
- 52 Week Low
- WIA $7.56
- NBTX $2.76
- 52 Week High
- WIA $8.91
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- WIA 55.39
- NBTX 53.25
- Support Level
- WIA $8.02
- NBTX $3.60
- Resistance Level
- WIA $8.35
- NBTX $3.95
- Average True Range (ATR)
- WIA 0.10
- NBTX 0.19
- MACD
- WIA 0.00
- NBTX -0.01
- Stochastic Oscillator
- WIA 57.58
- NBTX 38.18
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.